vorinostat has been researched along with Experimental Leukemia in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wittich, S | 1 |
| Scherf, H | 1 |
| Xie, C | 1 |
| Brosch, G | 1 |
| Loidl, P | 1 |
| Gerhäuser, C | 1 |
| Jung, M | 1 |
1 other study available for vorinostat and Experimental Leukemia
| Article | Year |
|---|---|
Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Cell Differentiation; Cell Division; Enzyme Inhibitors; | 2002 |